Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson tRACLEER (bosentan) [reported separately through FY2019Q4] — Worldwide sales ($M) ($M)
Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule
Latest, Q4 2019
56
Period ended Dec 29, 2019
Change on a year earlier
-54.8%
124 in Q4 2018
History
12 quarters
Since Q1 2017
Sources
8
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | TRACLEER (bosentan) [reported separately through FY2019Q4] — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2019 | Dec 29, 2019 | 56 | -54.8% | Form 10-K (filed 2020-02-18) ↗ |
| Q3 2019 | Sep 29, 2019 | 65 | -53.2% | Form 10-Q (filed 2019-10-28) ↗ |
| Q2 2019 | Jun 30, 2019 | 103 | -28.0% | Form 10-Q (filed 2019-07-29) ↗ |
| Q1 2019 | Mar 31, 2019 | 117 | -16.4% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 30, 2018 | 124 | -25.7% | Form 10-K (filed 2019-02-20) ↗ |
| Q3 2018 | Sep 30, 2018 | 139 | -33.8% | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2018 | Jul 1, 2018 | 143 | +450.0% | Form 10-Q (filed 2018-08-02) ↗ |
| Q1 2018 | Apr 1, 2018 | 140 | – | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2017 | Dec 31, 2017 | 167 | – | Form 10-K (filed 2019-02-20) ↗ |
| Q3 2017 | Oct 1, 2017 | 210 | – | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2017 | Jul 2, 2017 | 26 | – | Form 10-Q (filed 2018-08-02) ↗ |
| Q1 2017 | Apr 2, 2017 | 0 | – | Form 10-Q (filed 2018-05-01) ↗ |
Breakdown
What makes up tracleer (bosentan) [reported separately through fy2019q4] — worldwide sales ($m)
- TRACLEER (bosentan) [reported separately through FY2019Q4] — U.S. sales ($M)10 · Q4 2019
- TRACLEER (bosentan) [reported separately through FY2019Q4] — International sales ($M)46 · Q4 2019
- TRACLEER (bosentan) [reported separately through FY2019Q4] — Worldwide reported growth YoY (%)-28.0% · Q2 2019
- TRACLEER (bosentan) [reported separately through FY2019Q4] — Worldwide operational (constant-currency) growth YoY (%)-26.2% · Q2 2019
Cite this data
StockData. (2026). Johnson & Johnson TRACLEER (bosentan) [reported separately through FY2019Q4] — Worldwide sales ($M) ($M), quarterly Q1 2017–Q4 2019 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug_tracleer
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.